The following new uses for chloroquine and chloroquine analogs are provided:
- prevent hypoxia-reperfusion injury
- protect against lethal, "low dose rate" radiation
- treat metabolic syndrome (clinical trials ongoing)
chloroquine, metabolic syndrome, hypoxia-reperfusion injury, radiation
Granted Patents or Published Applications
U.S. Patent Nos. 6,916,627; 7,108,992; 7,160,692; 7,279,290; and 8,440,695, Pending U.S. Pub. 2013/0296237
Related Scientific References
Bakkenist, C. et al. ” DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation”, Nature 421: 499-506 (2003); see also related commentary by Bartek, J. and Lukas, J., Nature 421: 486-488 (2003);
Kastan, M.B. and Bartek, J., “Cell-cycle checkpoints and cancer”, Nature 432: 316-323 (2004);
Schneider, J.G. et al., “ATM-dependent suppression of stress signaling reduces vascular disease inmetabolic syndrome”, Cell Metab.4: 377-389 (Nov. 2006); see also related commentary by Shoelson, S., Cell Metab.4: 337-338 (Nov. 2006).
We are currently seeking nonexclusive licensing opportunities in the described fields for the development and use of this technology.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.